The BCM Ventures team is here to help guide Baylor faculty through collaborative drug discovery opportunities and find the right pathway towards commercialization. Benefits to working with our partners:
- We are working with long-term partners who have a proven track record of providing resources for commercial success.
- Our partners are committed to attracting leaders who have already driven a drug development process to industry and successfully led targets from clinical trials to market.
- With built-in resources that can efficiently develop assets, these partnerships can lead to faster time to market.
Internal Target Validation Committee
To help identify the most promising target candidates to bring into a drug discovery partnership, an Internal Target Validation Committee comprised of Baylor faculty has been established.
- Provide guidance and scientifically assess potential Baylor targets
- Direct promising targets to the appropriate collaboration
- Identify internal expertise and resources, which could aide in the development of the discovery and characterization of small molecules to potential targets
Chair: Salma Kaochar, Ph.D. MFA, Assistant Professor, Medicine – Hematology & Oncology and Oncology Section, Molecular & Cellular Biology, Dan L Duncan Comprehensive Cancer Center
- Malcolm Brenner, M.D., Ph.D., Professor, Center for Cell & Gene Therapy, Molecular & Human Genetics, Pediatrics, Medicine, Translational Biology & Molecular Medicine
- David Nelson, Ph.D., Professor, Molecular & Human Genetics
- Trey Westbrook, Ph.D., Professor, Molecular & Human Genetics, Biochemistry & Molecular Biology, Director, THINC
- Damian Young, Ph.D., Associate Director, Center for Drug Discovery, Assistant Professor, Pharmacology & Chemical Biology, Assistant Professor, Pathology & Immunology, Scientific Business Development Manager
Submitting a Target
Submission of your target is a multi-step certification process involving disclosure of the target, an understanding of the process defined by the College, and all target submission criteria with supporting documentation. Submissions will only be accepted from Baylor faculty.
Prior to submission, make sure to:
- Submit a disclosure to BCM Ventures via the IP Management System (for Baylor faculty-only)
- Have a listing of any funding sources (Federal or State funding (e.g. NIH, CPRIT), non-profit foundation funding, etc.)
- Have a listing of any connections with industry, such as a VC relationship, Sponsored Research Agreement (SRA), Research Collaboration Agreement (RCA), consulting agreement, Board seat, etc.
Submit your target (Baylor faculty-only)
Target Submission Criteria
The following details will be required to submit a target for commercial evaluation:
- Target/Gene Name
- Gene Symbol
- Uniprot ID
- Disease Area
- Have you or others identified a genetic link associating the target with a disease state? (e.g. GWAS/Mendelian, loss of function or gain of function mutation, change in mRNA levels, epigenetic changes, etc.)
- Is the target druggable? (supporting protein structure studies (e.g. crystallography), existing small molecule inhibitors, etc.)
- Have you developed functional assays? (functional cellular assays, knock-out/knock-in mouse models, etc.)
- Supporting Attachments
- Developers & Department or Institution (both BCM and non-BCM developers who have contributed to the development of this target)
- Funding Sources (Federal or State funding (e.g. NIH, CPRIT), non-profit Foundation funding, etc.)
- Special Affiliations (HHMI, VA, etc.)
- Public Disclosure